TT-00420 + nab-paclitaxel

TT-00420 + nab-paclitaxel is an investigational combination therapy under evaluation for the treatment of advanced solid tumors in early-phase clinical trials. **TT-00420** is a small molecule multikinase inhibitor with preclinical and early clinical evidence of activity in cancer, though the specific kinase targets are not detailed in the available data. **Nab-paclitaxel** (nanoparticle albumin-bound paclitaxel, marketed as Abraxane) is a microtubule inhibitor formulated to facilitate paclitaxel delivery without solvent, reducing hypersensitivity risk and allowing higher dosing. Nab-paclitaxel promotes the assembly and stabilization of microtubules, inhibiting their normal reorganization and blocking cell division in malignant cells. The combination is intended to explore potential synergistic antitumor effects by combining the targeted action of TT-00420 with the proven cytotoxicity of nab-paclitaxel[1][2][3][4][6].

Brand names

Abraxane

Other names

protein-bound paclitaxelpaclitaxel NAB